These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 22435662)
1. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Yano S; Takeuchi S; Nakagawa T; Yamada T Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662 [TBL] [Abstract][Full Text] [Related]
2. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343 [TBL] [Abstract][Full Text] [Related]
3. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
5. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482 [TBL] [Abstract][Full Text] [Related]
6. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
7. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661 [TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954 [TBL] [Abstract][Full Text] [Related]
10. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474 [TBL] [Abstract][Full Text] [Related]
11. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490 [TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840 [TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212 [TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR. Yang H; Wang R; Peng S; Chen L; Li Q; Wang W Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104 [TBL] [Abstract][Full Text] [Related]
16. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641 [TBL] [Abstract][Full Text] [Related]
17. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer. De Mello RA; Liu DJ; Aguiar PN; Tadokoro H Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060 [TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117 [TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]